Last reviewed · How we verify

XOMA 985 — Competitive Intelligence Brief

XOMA 985 (XOMA 985) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-15 inhibitor monoclonal antibody. Area: Immunology.

phase 3 IL-15 inhibitor monoclonal antibody IL-15 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

XOMA 985 (XOMA 985) — Symplmed Pharmaceuticals LLC. XOMA 985 is a monoclonal antibody that targets and inhibits IL-15, a key cytokine involved in immune cell activation and proliferation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
XOMA 985 TARGET XOMA 985 Symplmed Pharmaceuticals LLC phase 3 IL-15 inhibitor monoclonal antibody IL-15
N-803 N-803 National Cancer Institute (NCI) phase 3 IL-15 superagonist IL-15 receptor (IL-15R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-15 inhibitor monoclonal antibody class)

  1. Symplmed Pharmaceuticals LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). XOMA 985 — Competitive Intelligence Brief. https://druglandscape.com/ci/xoma-985. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: